Prelude Capital Management’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Prelude Capital Management’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-30,050	Closed	-$1.5K	–	1535
2022 Q4	$1.5K	Sell	30,050 -22,629	-43%	-$849	﹤0.01%	1247
2022 Q3	$3K	Hold	52,679	–	–	﹤0.01%	1402
2022 Q2	$5K	Hold	52,679	–	–	﹤0.01%	1644
2022 Q1	$19K	Buy	52,679 +30,050	+133%	+$13.2K	﹤0.01%	1550
2021 Q4	$11K	Buy	+22,629	New	+$12.8K	﹤0.01%	1882

Other funds holding CLDI.WS

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Prelude Capital Management's CLDI.WS Position: Q1 2023 in Review

Prelude Capital Management sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q1 2023, closing a stake of 30,050 shares — an estimated $1.5K sold.

Prelude Capital Management first reported a position in CLDI.WS in Q4 2021 and held it in 5 quarters. The position peaked at $19K in Q1 2022. 23 funds tracked by Wall St. Rank hold CLDI.WS as of Q1 2023.

Prelude Capital Management reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q1 2023 after selling out during the quarter.
Prelude Capital Management sold 30,050 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q1 2023, an estimated $1.5K.
Prelude Capital Management first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 5 quarters.
Prelude Capital Management's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $19K in Q1 2022.
23 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q1 2023.

Based on Prelude Capital Management's 13F filing for Q1 2023, filed 15 May 2023.